All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-04-12T13:13:11.000Z

What challenges arise in the management of AML in complete remission?

By Claire Baker, Georgia Scurfield, Maria Kasimati
Featured
Norbert Vey
Apr 12, 2021
Share:

Bookmark this article

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR. We asked, What challenges arise in the management of AML in complete remission?

What challenges arise in the management of AML in complete remission?

Recent improvements in induction chemotherapy have resulted in 70–80% of patients reaching complete remission, however, the majority will eventually relapse. In this video, Vey discusses the challenges and corresponding solutions in managing relapse, including:

  •  patient-related factors, such as age, cytogenetics, secondary AML, and minimal residual disease
  • targeted therapies, such as venetoclax, as an alternative to standard consolidation
  • maintenance strategies, combining different agents for elderly patients with AML

 

More about...
ChemotherapyEBMT 2021Venetoclax

Related articles

Add bookmark

How can venetoclax combinations be used in preparation for transplant?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax...

Dec 18, 2021
Add bookmark

How can venetoclax combinations be used in preparation for transplant?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer...

Dec 18, 2021
Add bookmark

ESH 2019 | What is the risk of developing AML in women previously treated for breast cancer?

Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, during the European School of Hematology (ESH) Translational Research Conference on AML.

Oct 31, 2019
Add bookmark

ESH 2019 | What is the risk of developing AML in women previously treated for breast cancer?

Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, during the European School of Hematology (ESH)...

Oct 31, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox